Yana V. Gridneva

Yana V. Gridneva

Auto-generated profile, based on publicly available information

Yana V. Gridneva

S.S. Yudin City Clinical Hospital, Moscow Healthcare Department; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2024 in Malignant tumours
Verified
Journal Article
Open access
PDF file
MVM. I. Volkova
M. I. Volkova
MFMikhail Fedyanin
Mikhail Fedyanin
IPIlya A. Pokataev
Ilya A. Pokataev
ИАИ. С. Аль-Акел
И. С. Аль-Акел
SVS. G. Vardanyan
S. G. Vardanyan
МФМ. Ю. Федянин
М. Ю. Федянин
Objective: to evaluate the efficacy of first-line systemic therapy administered in real clinical practice to patients >75 years old with prostate cancer (PCa).Material: the retrospective study included data from 315 patients >75 years old (median age — 84 (75-99) years) with hormone-sensitive PCa (HSPCa) who received antitumor therapy. Non-metastatic HSPCa (nmHSPCa) was observed in 223 (70,8%) patients, while metastatic HSPCa (mHSPCa) — in 92 (29,2%) patients. In 8 (3,6%) cases of nmHSPCa, bicalutamide monotherapy was prescribed, while androgen deprivation therapy (ADT) was administered in 215 (96,4%) cases (intermittently — 164 (73,5%)). All 92 patients with mHSPC received ADT, including in combinations corresponding to current clinical recommendations — in 38 (41,3 %) cases (with docetaxel — 17 (18,4 %), abiraterone acetate — 7 (7,6 %), enzalutamide — 10 (10,9 %), apalutamide — 1 (1,1 %)). The median follow-up time for patients with nmHSPC was 64,2 (2,1-275,7) months, for patients with mHSPC — 48,6 (1,0-234,3) months.Results: the median duration of the 1st line of therapy for nmHSPC was 40,6 (1,0-243,8) months. In nmHPRPC, PSA reduction by>90% during the first line of therapy was seen in 67,3 % of patients. Five-year survival of patients with nmHPRPC without PSA progression (PFPS) reached 70,8%, progression-free survival (PFS) — 70,8%, metastasis-free survival (MFS) — 85,0%, specific survival (SS) — 97,3% and overall (OS) — 91,5%. Continuous ADT in lowand intermediate-risk nmHPRPC reduced PFS compared to intermittent therapy (p = 0.014), but did not affect MFS, SS and OS. The median duration of the first line of therapy for mHPRPC was 14,3 (1,1-137,7) months. In mHSPC, the frequency of PSA decrease by>90% during the first line of therapy was 38,0%. In patients with mHSPC, the 4-year PFSSA was 50,1%, DFS — 50,1%, DFS — 83,5% and OS — 77,2%. In mHSPC, ADT compared with combination therapy reduced DFS (p = 0.018), DFS (p = 0.053) and OS (odds ratio 3.675 (95% confidence intervals: 1.001-13.489); p = 0.008). No significant effect of the combination drug on the survival of patients with mHSPC was found.Conclusions: in elderly patients with nmHSPC, intermittent ADT is not inferior to continuous ADT in terms of OS. In patients > 75 years old, combination therapy based on ADT with docetaxel or androgen signal inhibitors provides an increased OS compared to ADT alone.

18 December 2024 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
YGYana V. Gridneva
Yana V. Gridneva
DKDarya N. Khmelkova
Darya N. Khmelkova
MVMaria I. Volkova
Maria I. Volkova
KBKonstantin A. Blagodatskikh
Konstantin A. Blagodatskikh
AZAnna A. Zheludkevich
Anna A. Zheludkevich
ВАВещевайлов Александр Александрович
Вещевайлов Александр Александрович
Background. Genomic alterations in urothelial carcinoma (UC) cells range from point DNA mutations to complex chromosomal rearrangements and changes in the number of chromosomes in the tumor cell. The UC genetic profile is highly heterogeneous, leading to significant variability in the natural history of the disease, prognosis, and responses to treatment. To evaluate the genetic alterations of Russian patients with bladder cancer is of great interest. Aim. To evaluate the mutation profile in UC specimens with the next-generation sequencing (NGS) panel for 523 genes. Materials and methods. Thirty-six patients' UC samples fixed in formalin and embedded in paraffin were studied. Carcinoma in situ without papillary tumor was verified in 1 (2.9%), Ta in 14 (38.8%), T1 in 19 (52.7%), TT1 in 2 (5.6%) patients. High-grade UC was verified in 14 (38.9%) specimens. DNA and RNA were isolated from the paraffin blocks, libraries were prepared with the Illumina TruSight Oncology 500 panel, and then NGS was performed, followed by bioinformatics data processing. Results. The median tumor mutation burden (TMB) was 14.1 (1.6-102.9) mutations/Mb: TMB≥20 mutations/Mb – 6 (16.7%). In all cases, the level of microsatellite instability was low. In 36 specimens, 181 therapeutically significant and oncogenic mutations were identified in 62 genes; the median was 5 (1–16) mutations per specimen. Single nucleotide variants prevailed in the mutation structure: 123 (68%); GA had the highest frequency 36 (29.3%). There were 47 (26.0%) indel mutations, 10 (5.5%) amplifications, and 1 (0.6%) translocation. Clinically significant mutations were detected in all specimens. The highest frequency of clinically significant mutations was observed in the FGFR3 genes – 22 (61.1%) specimens with mutations in this gene, KDM6A – 22 (61.1%), STAG2 – 13 (36.1%), PIK3CA – 9 (25.0%), and ARID1A – 9 (25.0%). Pathogenic level 1-2 mutations providing potential therapeutic targets were detected in 29 (80.6%) of 36 specimens and included alterations of 13 genes (AKT1, ATM, BRAF, CHEK2, ERBB2, FGFR3, IDH1, MLH1, NF1, NRAs, PIK3CA, PTEN, and TSC1). Frequent mutations of level 3-4 therapeutic significance were in KDM6A (61.6%), ARID1A (25.0%), and CDKN2A (11.4%) genes. Conclusion. A 523-gene NGS panel study confirmed the high TMB and low rate of microsatellite instability in UC tumor cells. The most common pathogenic mutations associated with potential therapeutic targets in UC were FGFR3, PIK3CA, and ERBB2 alterations.

17 July 2025 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
MVMaria I. Volkova
Maria I. Volkova
KTKirill A. Turupaev
Kirill A. Turupaev
MFMargarita G. Filippova
Margarita G. Filippova
DLDaria D. Ladyko
Daria D. Ladyko
OSOgulshat R. Sinitsyna
Ogulshat R. Sinitsyna
VMVsevolod B. Matveev
Vsevolod B. Matveev
Background. Renal cell carcinoma (RCC) associated with von Hippel-Lindau syndrome (VHL) is characterized by multifocal bilateral involvement of the renal parenchyma and is the leading cause of death in this category of patients due to disease progression or the development of end-stage chronic kidney disease. Aim. To analyze the treatment outcomes of patients with RCC associated with VHL syndrome. Materials and methods. The ambispective study included data of 30 patients treated with VHL-associated RCC from 2016 to 2024. In 23 (76.7%) cases, VHL syndrome was classified as type 1, and in 7 (23.3%) as type 2B. Non-metastatic RCC at the initial diagnosis was detected in 28 (93.3%) patients and metastatic RCC in 2 (6.7%). Extrarenal manifestations of VHL syndrome occurred in all patients. Watchful waiting was used in 6 (20.0%) patients, surgical treatment of renal parenchyma tumors in 21 (70.0%), metastasectomy – in 2 (6.7%), and systemic antitumor therapy in 3 (10.0%). Treatment of extrarenal manifestations of VHL syndrome included surgical interventions in 20 (66.7%) patients, radiation therapy in 8 (26.7%), and laser therapy in 9 (30.0%). The median follow-up for all patients from the RCC detection was 46.6 [1-249.5] months. Results. The four-year overall (OS) and disease-specific (DSS) survival rates for all 30 patients were 93.3% and 93.3%, respectively. In 28 patients with primary non-metastatic RCC, the 4-year metastasis-free survival (MFS) was 74.2%. In 21 patients after radical surgery for the primary non-metastatic renal cell carcinoma, the 4-year OS was 88.9%, DSS was 88.9%, relapse-free survival (RFS) was 62.9%, local recurrence-free survival was 53.9%, and MFS was 63.6%. In patients with distant metastases, the 4-year OS was 66.7%. Two (6.7%) patients developed terminal chronic kidney disease requiring permanent hemodialysis. Conclusion. VHL-associated RCC is a chronic disease with a torpid course, allowing to recommend organ-sparing treatment of primary tumors and metastasis-directed therapy of oligometastases. Antiangiogenic therapy is effective in metastatic RCC.

11 November 2024 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
IPIlya A. Pokataev
Ilya A. Pokataev
OSOlesya A. Stativko
Olesya A. Stativko
MVMaria I. Volkova
Maria I. Volkova
AFAlina N. Fedorova
Alina N. Fedorova
EZElena V. Zueva
Elena V. Zueva
VGVsevolod N. Galkin
Vsevolod N. Galkin
Aim. To compare of efficacy and safety of combined immune therapy (dual immune-oncology – IO combination therapies, IO-IO) and immune targeted therapy (ITT) in the first line treatment of patients with advanced renal cell carcinoma (RCC) treated in real world clinical practice. Materials and methods. The ambispective study enrolled patients with metastatic RCC aged ≥18 years, with measurable neoplastic lesions, who were treated with first-line IO-IO therapy or ITT. The primary endpoint was progression-free survival (PFS). Results. The study included data from 126 patients treated with IO-IO [46 (36.5%) patients of the IMDC intermediate and poor prognostic groups] or ITT [80 (63.5%) patients of all IMDC prognostic groups]. In a median follow-up of all patients of 16.1 (0.1–44.9) months, the median PFS was 16.1 (10.9–21.3) months, the median overall survival (OS) was not reached; one-year OS was 83.0%; the objective response rate on the first line of therapy was 44.4% with a complete response rate of 3.2%. The rate of tumor control was 88.1%. In the overall population, ITT versus IO-IO provided a significant benefit in terms of ORR (51.2% vs 32.6%; p=0.032), PFS (median 22.9 months vs 8.0 months; p=0.004) and one-year OS (87.5% vs 65.2%; p=0.042). In the IPTW population, multivariate analysis confirmed the independent prognostic significance of the treatment regimen for PFS (hazard ratio, 2.3; 95% confidence interval, 1.1–4.8; p=0.037) and OS (hazard ratio, 2.3; 95% confidence interval 1.1–4.8; p=0.037). No difference in the safety profile of IO-IO and ITT was identified. Conclusion. The results support the hypothesis that ITT is more effective than IO-IO in the first-line treatment of advanced RCC in patients of IMDC intermediate and poor prognostic groups.

30 August 2024 in Consilium Medicum
Verified
Journal Article
Open access
PDF file
SPSergey A. Parts
Sergey A. Parts
YGYana V. Gridneva
Yana V. Gridneva
MVMaria I. Volkova
Maria I. Volkova
AOAlbert V. Oskarev
Albert V. Oskarev
OSOgulshat R. Sinitsyna
Ogulshat R. Sinitsyna
SGSaida M. Gadzhieva
Saida M. Gadzhieva
Background. The clinical course of non-muscle-invasive bladder cancer is characterized by a tendency to develop local recurrences and the ability to tumor progression. The most effective method of preventing disease progression after transurethral resection of the bladder in patients of intermediate and high-risk groups is intravesical therapy with BCG antitumor vaccine containing attenuated Mycobacterium tuberculosis. Taking into account the increasing incidence non-muscle-invasive bladder cancer in Moscow, the organization of adequate use of BCG vaccine in clinical practice requires the involvement of significant organizational and human resources. Aim. To develop and validate an organizational model for the delivery of BCG therapy for non-muscle-invasive bladder cancer at an outpatient cancer care center using hospital-substitution technologies. Materials and methods. In the period from June 2023 to May 2024, BCG therapy has been performed in Oncology Center №1 of Yudin Moscow City Hospital in 180 patients with verified non-muscle-invasive bladder cancer of intermediate and high-risk groups. Results. The study revealed a trend towards an increase in the absolute number of early bladder cancer in Moscow in the period 2018–2023. According to clinical guidelines, treatment of patients with non-muscle-invasive bladder cancer includes determination of the risk of recurrence and tumor progression with subsequent formation of indications for intravesical BCG therapy. The regimen of administration depending on the risk of recurrence includes 18–42 instillations for 12–36 months after transurethral resection of the bladder with follow-up examinations every three months. The procedure of intravesical BCG therapy takes 1–2 hours and does not require hospitalization. An organizational model of treatment an outpatient cancer care center based on various forms of hospital-substitution technologies is presented. Conclusion. Intravesical BCG therapy is a highly demanded method for the treatment of non-muscle-invasive bladder cancer. This method can be widely used in outpatient settings through the use of hospital-substitution technologies.

4 March 2026 in Malignant tumours
Verified
Journal Article
Open access
PDF file
YGYa. V. Gridneva
Ya. V. Gridneva
MVM. I. Volkova
M. I. Volkova
YAYu. V. Anzhiganova
Yu. V. Anzhiganova
VBV. S. Bragina
V. S. Bragina
ВВВ. А. Водолазский
В. А. Водолазский
Ilya V. TsimafeyeuIlya V. Tsimafeyeu
Ilya V. Tsimafeyeu
Objective: To evaluate the efficacy and safety of avelumab maintenance therapy in patients with metastatic urothelial carcinoma (UC) in real-world practice. Methods: This ambispective study included patients with metastatic UC and measurable tumor lesions, without progression during and after first-line platinum-based chemotherapy (CHT), who received avelumab maintenance therapy (800 mg IV every 2 weeks). The primary endpoint of the study was overall survival (OS). Results: The study included 110 patients, with a predominance of men (81 %). The median age of all patients was 65 (range, 36–84) years. With a median follow-up of 11.9 months, the median OS was not reached; the one-year OS was 78.7 %. The median progression-free survival (PFS) was 9.5 months (95 % CI, 7.8–11.2 months). The objective response rate (ORR) to first-line chemotherapy was 48.2 %. Of the 97 patients with an evaluated objective response, 38 (39.2 %) demonstrated additional objective responses to avelumab therapy (16 complete and 22 partial responses). Grade 3 adverse events during avelumab therapy were observed in 11.8 % of patients. Conclusions: The efficacy and safety of avelumab maintenance therapy in real-world practice are comparable to those in the pivotal study.